Cor Vasa 2011, 53(10):527-534 | DOI: 10.33678/cor.2011.132
How are statins used in the Czech Republic? STEP survey - results
- 1 III. interní klinika, 1. lékařská fakulta Univerzity Karlovy a Všeobecné fakultní nemocnice, Praha
- 2 Farmakologický ústav, 3. lékařská fakulta Univerzity Karlovy, Praha
- 3 AstraZeneca Czech Republic, s.r.o., Praha
- 4 ADDS, s.r.o., Brno, Česká republika
Objective: Statins are one of the most prescribed medications in our country. About 2 billions CZK are being paid for them annually in the Czech Republic (CR). Objective information about to whom, why, how, by whom and with what results these medications are given is, however, missing. It was the aim of the STEP project (Statin Therapy REsults in the Real World Practice in the Czech Republic), which was carried out in the CR in 2010, to obtain the missing information.
Patients and methods: In this non-intervention retrospective survey, data from 3190 patients treated by statins for at least 12 months in specialized outpatient clinics were collected and analyzed. The primary aim was to establish the percentage of patients who attain the LDL cholesterol (LDL-C) goal during the treatment with statin lasting for at least 12 months. The patients were divided into 3 groups according to their absolute cardiovascular (CV) risk and the LDL-C goal was defined for each of these groups based on the current recommendations - group 1: primary prevention (n = 597) - LDL-C < 3.0 mmol/l; group 2: secondary prevention (n = 1901) - LDL-C < 2.5 mmol/l; group 3: very high CV risk (n = 692) - LDL-C < 2.0 mmol/l.
Results: The mean patients' age was 63 years, 59% of the patients were males. Mean BMI = 29.3 ± 4.6 kg/m2, systolic BP = 134 ± 15 mmHg and diastolic BP = 80 ± 9 mmHg. The mean duration of the treatment with statins was 3.7 ± 2.9 years with a median of 3 years. The mean baseline LDL cholesterol concentration of 3.58 ± 1.24 mmol/l decreased during the treatment with statins lasting for at least 12 months by 0.98 mmol/l (-22%). The LDL cholesterol goal corresponding to the given CV risk was attained in 46% of all patients (by 64% in group 1; by 50% in group 2; by 20% in group 3). LDL cholesterol concentration
Keywords: LDL cholesterol; Treatment of dyslipidemia; STEP survey; Statins
Published: October 1, 2011 Show citation
References
- Zemřelí 2009. Praha: Ústav zdravotnických informací a statistiky ČR, 2010; www.uzis.cz.
- Zdravotnictví České republiky 2008 ve statistických údajích. Praha: Ústav zdravotnických informací a statistiky, 2009; www.uzis.cz.
- Cífková R, Býma S, Češka R, et al. Prevence kardiovaskulárních onemocnění v dospělém věku. Společná doporučení českých odborných společností. Cor Vasa 2005;47(Suppl 9):3-14.
- Býma S, Hradec J. Prevence kardiovaskulárních onemocnění. Novelizace 2009. Doporučený diagnostický a léčebný postup pro všeobecné praktické lékaře. Centrum Doporučených postupů pro praktické lékaře. Praha: Společnost všeobecného lékařství ČLS JEP, 2009, 12 s.
- Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278.
Go to original source...
Go to PubMed...
- Ballantyne CM. Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol 1998;82:3Q-12Q.
Go to original source...
Go to PubMed...
- Vaverková H, Soška V, Rosolová H, et al. Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti. Cor Vasa 2007;49:K73-K86.
- Hahn GJ, Meeker WQ. Statistical intervals: A guide for practitioners. New York: John Wiley & Sons Inc., 1991.
Go to original source...
- Králíková E, Býma S, Cífková R, et al. Doporučení pro léčbu závislosti na tabáku. Čas Lék Čes 2005;144:327-333.
- Čupka J, Nešpor K, Králíková E, et al. Léčba závislosti na tabáku v ordinaci praktického lékaře. Doporučený diagnostický a léčebný postup pro všeobecné praktické lékaře. Praha: CDL-PL, 2005.
- Výbor ČDS ČLS JEP. Doporučený postup péče o diabetes mellitus 2. typu. Aktualizace 2009. http://www.diab.cz/dokumenty/dm2_2009.pdf.
- Karen I, Kvapil M, Býma S, Herber O. Diabetes mellitus. Doporučený diagnostický a léčebný postup pro všeobecné praktické lékaře. Praha: CDL-PL, 2005.
- Cífková R, Škodová Z, Lánská V, et al. Trends in blood pressure levels, prevalence, awarness, treatment, and control of hypertension in the Czech population from 1985 to 2000/01. J Hypertens 2004;22:1479-1485.
Go to original source...
Go to PubMed...
- Vrablík M, Freiberger T, Lánská V, Češka R. Projekt Atractiv: zlepšení kardiovaskulární prevence v podmínkách primární péče v České republice. Vnitř Lék 2008;54:1131-1139.
Go to PubMed...
- Cífková R, Hradec J, Švihovec J, Býma S. Projekt FIAKR. Plán projektu a vstupní data z okresu Mladá Boleslav. Kap Kardiol 2009;1:107-110.
- Jones PH, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patiens with hypercholesterolemia (the CURVES study). Am J Cardiol 1988;81:582-587.
Go to original source...
Go to PubMed...
- Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003;93:152-160.
Go to original source...
Go to PubMed...